Study: Apixaban performs comparably with warfarin

07/1/2013 | Reuters · Forbes

The anticoagulant apixaban performed comparably with the standard treatment warfarin in a trial involving 5,395 patients with acute venous thromboembolism, according to findings published in the New England Journal of Medicine. The new drug reduced the risk of major bleeding by around 70% and clinically relevant non-major bleeding by more than 50%, the study said. The AMPLIFY trial randomized the patients to either conventional therapy with enoxaparin and warfarin or apixaban. The findings "add to the evidence that the new oral anticoagulants are simple alternatives to conventional therapy for patients with acute venous thromboembolism," researchers wrote.

View Full Article in:

Reuters · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY